OptimizeRx

As the year draws to a close, pharma brands are deep in the media planning process for 2025. But despite seemingly endless amounts of information available, most “data driven” strategies still contain assumptions and uncertainties that can undermine advertising performance and lead to wasted spend, missed patients, and competitive disadvantages.

This webinar examines how integrating quantitative data on condition and market-specific, de-identified patients with their media preferences, interests, and demographics can generate insights that enhance patient engagement, inform media investments, and strengthen advertising effectiveness.

Speakers:
Karin Hayes, SVP, Analytics & Insights - OptimizeRx
Mike Czuba, Vice President, Head of Account Planning - AbelsonTaylor

Moderator:
Megan Solimine, SVP Sales - OptimizeRx

Early treatment is a fundamental principle of MS disease management to help lower the risk of disease progression and prevent disability. However, patient awareness of the positive impact of early treatment and long-term continuous therapy remains an issue in MS disease management. Understanding key factors that delay new patient starts on therapy are critical to reaching and educating patients and getting them on the right therapy early on to prevent disease progression and keeping them adherent to prevent disability.

While pharma has been using real world data (RWD) to generate real world evidence (RWE) for clinical trials, post-marketing, and R&D for decades, the emergence and applicability of RWD to the sales, marketing, and commercial side of the house is now ramping up. Many organizations are exploring the possibilities related to targeting, segmentation, sales force effectiveness, and adherence, allocating growing budgets to acquire, analyze, and visualize data. How can pharma manufacturers leverage those resources to ensure they’re engaging HCPs and patients in a timely and precise manner to increase early start of MS treatment? That’s where advanced analytics in RWD translate into actionable insights that can drive positive outcomes.

In this webinar we’ll discuss how applications in advanced analytics and machine learning, can leverage clinical expertise in analyzing RWD to create predictive profiles of patients who meet the criteria for early MS treatment. In the same way, advanced analytics i can be applied to identify HCPs treating those patients along the journey and predict the best moments to share MS treatment information with those HCPs at the point of care – within their workflow. This ability to reach HCPs supports a proactive approach to treatment since they can be reached using an omni-channel approach, providing information beyond the EHR and even when they’re not with the patients.

Presenters:

• Eze K. Abosi, Head, Real World Evidence Solutions
• Adam Almozlino, Vice President, Data & Products, OptimizeRx
• Mark Bard, Co-Founder, The DHC Group
• Rebecca Love, RN, MSN, FIEL